

in which

- R₁, R₂, R₃, and R₄ are independently of each other, H, OH, a C₁-C₄ alkoxy group, or an -OCOR₇ group, R₇ being a C₁-C₄ alkyl group, at least one of the substituents R₁, R₂, R₃, and R₄ being other than H and it being possible for R₂ and R₃ to form together a methylenedioxy group;

- R₅ is H, OH, a C₁-C₄ alkoxy group, an O-glycosyl group, or a cyclohexyl group;

R₆ is a cyclohexyl group, a phenyl group, or a phenyl group substituted 1 to 3 times with H, OH, or a C₁-C₄ alkoxy group;

- and denotes either a double bond, or a single bond.

REMARKS

Applicant wishes to thank the examiner for acknowledging in the Office Action the claim to foreign priority under 35 USC 119 and receipt of the certified copy of the priority document, as requested.

Claims 16 and 18-24 are pending.

By the instant amendment claim 16 is amended. As amended hereby, method-of-treatment claim 16 involves administering "a cytotoxic potentiating amount of an isoflavonoid," instead of "a therapeutically effective" amount of the isoflavonoid. As such, what was implicit in claim 16 as originally submitted is, now, expressly recited in claim 16 as amended.